Entera Bio reports Q2 results: submits EB613 protocol to FDA, net loss $7.0M, cash $17.3M

Entera Bio Ltd.

2022-Q2 EPS reported $0.24 revenue$112,000

Submitted proposed registrational protocol for EB613 (oral PTH) to FDA; expects Type C meeting in H2 2022.
Finalizing optimized formulation for EB612 (hypoparathyroidism); first-in-human PK study planned H1 2023.
Net loss $7.0M ($0.24 per share) for six months ended June 30, 2022, vs $4.9M ($0.21) in prior year period.
Revenue $112k, down from $226k; operating expenses $7.1M, up from $5.0M.
Cash $17.3M as of June 30, 2022, expected to fund operations through Q2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.